Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-05-14
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004925
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-05-14
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004928
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004059
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00004052
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
- Conditions
- Breast CancerLung CancerProstate Cancer
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00059943
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00059904
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Polyglutamate Camptothecin in Treating Patients With Advanced Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00059917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00059995
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
- Conditions
- Anal CancerColorectal CancerPerioperative/Postoperative Complications
- Interventions
- Procedure: conventional surgeryProcedure: management of therapy complications
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00059891
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
- Conditions
- Colorectal CancerMetastatic Cancer
- Interventions
- Drug: FOLFOX regimenProcedure: adjuvant therapyProcedure: conventional surgery
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00059930
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States